CareDx, Inc. (Nasdaq: CDNA) announced it will present data from more than 30 abstracts and nine oral presentations at the American Transplant Congress (ATC) 2026, scheduled for June 20–24 in Boston, Massachusetts.

The presentations will cover findings related to AlloSure Kidney, AlloSure Plus, HistoMap Kidney, HeartCare, AlloMap Heart, AlloSure Heart, and AlloSure Lung, drawing on studies conducted at more than 110 transplant centers across the United States.

According to the company, data from the studies show AlloSure donor-derived cell-free DNA is being evaluated as a potential clinical endpoint for assessing allograft injury, monitoring treatment response, and evaluating long-term graft health in kidney transplantation.

Key kidney transplant findings include a multicenter analysis of more than 4,000 recipients across 28 centers, in which elevated AlloSure was independently associated with microvascular inflammation phenotypes. A separate study found AlloSure Plus scores showed an AUROC of 0.79 for discriminating rejection in biopsy-confirmed cases.

In heart transplantation, higher AlloMap scores were associated with subsequent elevations in AlloSure Heart, with increased risk observed at gene expression profiling scores of 25 or above.

CareDx also reported findings from its ImmuneScape single-cell and spatial transcriptomics platform, which identified distinct immune cell populations and spatial infiltration patterns associated with kidney allograft rejection.

CareDx will host a symposium on June 21, 2026, featuring case-based discussions on AlloSure Kidney and AlloSure Plus, including data from the second published manuscript of the KOAR study. The panel will include transplant nephrologists from Northwestern Medicine, NYU Langone, the University of Washington, and Weill Cornell Medicine.